Payment overview · 2025
General Payments
$1,077.19
40 reported records · 15 companies
Healthcare provider profile · identity verified
Luis Cardentey, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FORT MYERS, FL · NPI 1457640666
Verified facts
What the public records show
CMS Open Payments records show Luis Cardentey, M.D. received $1,077.19 in general payments during 2025 across 40 reported records.
Optinose US, Inc. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Otezla.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $257.08 | 23.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $190.77 | 17.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $186.17 | 17.3% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $99.84 | 9.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.84 | 6.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $68.86 | 6.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.68 | 3.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.41 | 3.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.95 | 2.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.58 | 2.1% | 1 | 2025 |
| Amicus Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.02 | 1.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.72 | 1.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.33 | 1.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.63 | 1.4% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $15.31 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,077.19 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $257.08 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $185.58 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $99.84 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $82.87 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $73.17 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $70.84 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $68.92 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.34 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.51 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $42.67 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.68 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $5.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 53 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 105 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
105 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 109 |
| Metformin Hcl | Metformin Hcl | 299 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 276 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 249 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 86 |
| Alprazolam | Alprazolam | 217 | 42 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 204 | 64 |
| Lisinopril | Lisinopril | 190 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 58 |
| Omeprazole | Omeprazole | 146 | 44 |
| Losartan Potassium | Losartan Potassium | 130 | 43 |
| Prednisone | Prednisone | 126 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 41 |
| Gabapentin | Gabapentin | 107 | 37 |
| Farxiga | Dapagliflozin Propanediol | 105 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 31 |
| Celecoxib | Celecoxib | 97 | 25 |
| Tramadol Hcl | Tramadol Hcl | 96 | 32 |
| Azithromycin | Azithromycin | 87 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 25 |
| Simvastatin | Simvastatin | 71 | 23 |
| Trazodone Hcl | Trazodone Hcl | 71 | 22 |
| Clonazepam | Clonazepam | 69 | suppressed |
| Ozempic | Semaglutide | 69 | 19 |
| Trulicity | Dulaglutide | 68 | 15 |
| Montelukast Sodium | Montelukast Sodium | 67 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 22 |
| Famotidine | Famotidine | 66 | 19 |
| Meloxicam | Meloxicam | 66 | 24 |
| Allopurinol | Allopurinol | 63 | 18 |
| Ezetimibe | Ezetimibe | 63 | 21 |
| Temazepam | Temazepam | 62 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 58 | 31 |
| Lovastatin | Lovastatin | 55 | 14 |
| Eliquis | Apixaban | 53 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 22 |
| Mounjaro | Tirzepatide | 53 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 52 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 18 |
| Mirtazapine | Mirtazapine | 46 | 12 |
| Furosemide | Furosemide | 45 | 21 |
| Sertraline Hcl | Sertraline Hcl | 45 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Gemfibrozil | Gemfibrozil | 43 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 19 |
| Jardiance | Empagliflozin | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 16 |
| Carvedilol | Carvedilol | 36 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 14 |
| Lorazepam | Lorazepam | 35 | 12 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Torsemide | Torsemide | 30 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Atenolol | Atenolol | 27 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 11 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Clindamycin-Benzoyl Peroxide | Clindamycin Phos/Benzoyl Perox | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Quviviq | Daridorexant Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,077.19 · 40 records | Optinose US, Inc. | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, Flector, JARDIANCE, LEQVIO, Licart, NEXLETOL, NURTEC ODT, OTEZLA, REPATHA, The Cologuard Plus Collection Kit, Tirosint, VRAYLAR, Wegovy, XYOSTED, Xhance, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error